AI Article Synopsis

  • * A preclinical trial evaluated the effects of two corticosteroids, vamorolone (dissociative) and prednisolone (conventional), on inflammation and organ dysfunction in sickle cell disease mice.
  • * While both corticosteroids reduced inflammation and white blood cell counts, they also caused significant liver damage, highlighting possible risks of hepatic toxicity despite reduced inflammation in sickle cell disease patients.

Article Abstract

Clinicians often hesitate prescribing corticosteroids to treat corticosteroid-responsive conditions in sickle cell disease (SCD) patients because their use can be associated with complications (increased hospital readmission, rebound pain, strokes, avascular necrosis, acute chest syndrome). Consequently, SCD patients may receive suboptimal treatment for corticosteroid-responsive conditions. We conducted a preclinical trial of dissociative (vamorolone) and conventional (prednisolone) corticosteroid compounds to evaluate their effects on nociception phenotype, inflammation, and organ dysfunction in SCD mice. Prednisolone and vamorolone had no significant effects on nociception phenotype or anemia in homozygous mice. Conversely, prednisolone and vamorolone significantly decreased white blood cell counts and hepatic inflammation. Interestingly, the effects of vamorolone were milder than those of prednisolone, as vamorolone yielded less attenuation of hepatic inflammation compared to prednisolone. Compared to controls and heterozygotes, homozygotes had significant liver necrosis, which was significantly exacerbated by prednisolone and vamorolone despite decreased hepatic inflammation. These hepatic histopathologic changes were associated with increases in transaminases and alkaline phosphatase. Together, these results suggest that, even in the setting of decreasing hepatic inflammation, prednisolone and vamorolone were associated with significant hepatic toxicity in SCD mice. These findings raise the possibility that hepatic function deterioration could occur with the use of corticosteroids (conventional and dissociative) in SCD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904156PMC
http://dx.doi.org/10.1038/s41598-018-24274-6DOI Listing

Publication Analysis

Top Keywords

prednisolone vamorolone
24
hepatic inflammation
16
nociception phenotype
12
corticosteroid compounds
8
prednisolone
8
vamorolone
8
sickle cell
8
corticosteroid-responsive conditions
8
scd patients
8
effects nociception
8

Similar Publications

Article Synopsis
  • - The CAS3D image processing method combines Fourier and real space algorithms to analyze 3D volumetric images of skeletal muscle fibers, allowing for automated quantification of myofibrillar orientation and mean sarcomere length (SL).
  • - The method demonstrated strong reliability, reproducing expected results from ideal data sets, while showing that slight random noise (up to 20%) had a linear effect on CAS3D values without significantly affecting SL and orientation detection.
  • - When applied to a rat ICU model studying ventilator-induced diaphragm dysfunction, CAS3D improved the standard deviation of cosine angle sum detection from 0.03 to 0.008 by processing entire 3D images rather than slice-by-slice, enhancing
View Article and Find Full Text PDF

Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.

J Neuromuscul Dis

November 2023

Department of Anatomy, Physiology and Human Biology, School of Human Sciences, The University of Western Australia, Perth, Western Australia, Australia.

Article Synopsis
  • Vamorolone (VBP15) is being explored as an alternative to traditional glucocorticoids like prednisone and deflazacort for treating Duchenne muscular dystrophy (DMD), aiming to reduce adverse side effects while maintaining anti-inflammatory efficacy.
  • Clinical trials indicate that vamorolone shows similar effectiveness to existing treatments but with potentially fewer negative effects, particularly regarding growth-related issues.
  • Ongoing research aims to determine the best clinical dosage and additional benefits of vamorolone, including its ability to stabilize muscle cell membranes and enhance repair, while also comparing its long-term efficacy and cost with other treatments.
View Article and Find Full Text PDF
Article Synopsis
  • - Duchenne muscular dystrophy (DMD) is a severe genetic disorder leading to muscle loss and early mortality, with corticosteroids like deflazacort (FDA approved) and prednisone/prednisolone being standard treatments, while vamorolone is a new candidate under investigation.
  • - In studies using a mouse model for DMD, vamorolone demonstrated unique pharmacokinetic properties, showing significant central nervous system (CNS) exposure compared to the other corticosteroids, which are strong p-glycoprotein substrates.
  • - Although all three corticosteroids displayed effectiveness, they also caused side effects; especially, prednisolone and vamorolone were linked to changes in brain gene expression and depression-like behaviors, along
View Article and Find Full Text PDF

Advances in Dystrophinopathy Diagnosis and Therapy.

Biomolecules

August 2023

Department of Neurosciences, Padova University School of Medicine, Via Giustiniani 5, 35128 Padova, Italy.

Article Synopsis
  • Dystrophinopathies are genetic muscular disorders linked to mutations in the dystrophin gene, including Duchenne and Becker muscular dystrophy, which can lead to issues like osteoporosis that worsen with certain treatments.
  • Diagnosis involves several techniques, such as creatine kinase assays and DNA sequencing, while treatment options include glucocorticoids and heart medications to prevent complications.
  • Emerging gene therapies, particularly antisense oligonucleotide drugs like eteplirsen, target specific gene defects and show promise for improving outcomes in a subset of Duchenne muscular dystrophy patients.
View Article and Find Full Text PDF
Article Synopsis
  • * Researchers tested a drug called vamorolone, originally developed for Duchenne muscular dystrophy, in a mouse model of BMD and found it improved grip strength and muscle function while reducing harmful side effects compared to another steroid, prednisolone.
  • * Vamorolone not only assisted in muscle recovery but also increased levels of dystrophin protein in both heart and skeletal muscle, suggesting it could be a promising therapy for BMD and warrant further research in clinical settings.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!